Faculty Bibliography

Introduction/UNASSIGNED:This study assessed the incidence and risk factors for pseudarthrosis among primary spine fusion patients. Methods/UNASSIGNED:-tests. Binary logistic regression assessed patient-related and procedure-related predictors for pseudarthrosis. Results/UNASSIGNED:=0.026). Conclusions/UNASSIGNED:Alcoholism and surgical revision are major risk factors for pseudarthrosis in patients undergoing spine fusion.

OBJECTIVE:We describe FDG-PET/CT findings of postoperative fat necrosis in patients following abdominal surgery, and evaluate their changes in size and FDG uptake over time. METHODS:FDG-PET/CT scans from January 2007-January 2016 containing the term 'fat necrosis' were reviewed. Lesions meeting radiological criteria of fat necrosis in patients with prior abdominal surgery were included. RESULTS:Forty-four patients, 30 males, mean age 68.4 ± 11.0 years. Surgeries: laparotomy (n=37; 84.1 %), laparoscopy (n=3; 6.8 %), unknown (n=4; 9.1 %). CTs of all lesions included hyperdense well-defined rims surrounding a heterogeneous fatty core. Sites: peritoneum (n=34; 77 %), omental fat (n=19; 43 %), subcutaneous fat (n=8; 18 %), retroperitoneum (n=2; 5 %). Mean lesion long axis: 33.6±24.9 mm (range: 13.0-140.0). Mean SUVmax: 2.6±1.1 (range: 0.6-5.1). On serial CTs (n=34), lesions decreased in size (p=0.022). Serial FDG-PET/CT (n=24) showed no significant change in FDG-avidity (p=0.110). Mean SUVmax did not correlate with time from surgery (p=0.558) or lesion size (p=0.259). CONCLUSION/CONCLUSIONS:Postsurgical fat necrosis demonstrated characteristic CT features and may demonstrate increased FDG uptake. However, follow-up of subsequent imaging scans showed no increases in size or FDG-avidity. Awareness of this entity is important to avoid misinterpretation of findings as recurrent cancer. KEY POINTS/CONCLUSIONS:• Postsurgical fat necrosis may mimic cancer in FDG-PET/CT. • Follow-up of fat necrosis showed no increase in FDG intensity. • CT follow-up showed a decrease in lesion size. • FDG uptake did not correlate with time lapsed from surgery.

OBJECTIVES/OBJECTIVE:Patients with clinically localized prostate cancer but markedly elevated prostate-specific antigen (PSA) are often treated with systemic agents alone. We hypothesized that they would benefit from radiation therapy. METHODS:We utilized the Survival, Epidemiology and End Results (SEER) Database for patients diagnosed with nonmetastatic prostate cancer from 2004 to 2008. Patients treated surgically or with brachytherapy were excluded. Survival was analyzed using the Kaplan-Meier method and Cox proportional hazard models. Propensity score was used to adjust for the nonrandomized assignment of local therapies. RESULTS:A total of 75,539 nonmetastatic prostate cancer patients were identified who received either radiotherapy or no local treatment. Median age was 70 years. Median follow-up of alive subjects was 60 months, with an interquartile range of 47 to 77 months. Estimated 4-year overall survival of entire population was 88%. Significant prognostic variables for overall survival on multivariate analysis included age, grade, PSA level, T stage, and use of radiation therapy. Use of radiation therapy was the most powerful predictor of both cause-specific and overall survival (HR=0.41 and 0.46, respectively, P<0.001). The benefit conferred by local treatment was seen even in subjects with PSA≥75 ng/mL. Four-year cancer-specific survival was 93.8% in those receiving radiation treatments versus 76.5% in those who did not receive any local treatment. CONCLUSIONS:Survival was significantly improved by radiotherapy for localized prostate cancer. Extremely high PSA levels (≥25 ng/mL) should not be considered a contraindication to local treatment.

Aims: Patients with cleft lip and/or palate (CL/P) can undergo numerous procedures to improve appearance, speech, dentition and hearing. We developed a cleft-specific patient-reported outcome (PRO) instrument to facilitate rigorous international measurement and benchmarking. Methods: Data were collected from patients aged 8 to 29 years with CL/P at 30 hospitals in 12 countries between October 2014 and November 2016. Rasch measurement theory (RMT) analysis was used to refine the scales and to examine reliability and validity. Normative CLEFT-Q values were computed for age, gender and cleft type. Results: Analysis led to the refinement of an eating/drinking checklist and 12 scales measuring appearance of the face, nose, nostrils, teeth, lips, jaws and cleft lip scar), health-related quality of life psychological, social, school, speech-related distress) and speech function. All scales met the requirements of the Rasch model. Analysis to explore differential item function by age, gender and country provided evidence to support the use of a common scoring algorithm for each scale for international use. Hypotheses that poorer outcomes would be associated with having a speech problem, being unhappy with facial appearance, and needing future cleft-related treatments were supported. Normative values for age, gender and cleft type showed poorer outcomes associated with older age, female gender and having a visible cleft. Conclusions: The CLEFT-Q represents a rigorously developed PRO instrument that can be used internationally to collect and compare evidence-based outcomes data from patients aged 8 to 29 years of age with CL/P

PURPOSE:: The FDA approved C-11 choline PET/computed tomography (CT) for imaging patients with recurrent prostate cancer in 2012. Subsequently, the 2014 NCCN guidelines have introduced labeled choline PET/CT in the imaging algorithm of patients with suspected recurrent disease. However, there is only scarce data on the impact of labeled choline PET/CT findings on disease management. We hypothesized that labeled-choline PET/CT studies showing local or regional recurrence or distant metastases will have a direct role in selection of appropriate patient management and improve radiation planning in patients with disease that can be controlled using this mode of therapy. METHODS:: This retrospective study was approved by the Tel Aviv Sourasky and Sheba Medical Center's Helsinki ethical review committees. Patient characteristics including age, PSA, stage, prior treatments, and pre-PET choline treatment recommendations based on NCCN guidelines were recorded. Patients with biochemical failure and without evidence of recurrence on physical examination or standard imaging were offered the option of additional imaging with labeled choline PET/CT. Treatment recommendations post-PET/CT were compared with pre-PET/CT ones. Pathologic confirmation was obtained before prostate retreatment. A nonparametric chi test was used to compare the initial and final treatment recommendations following choline PET/CT. RESULTS:: Between June 2010 and January 2014, 34 labeled-choline PET/CT studies were performed on 33 patients with biochemical failure following radical prostatectomy (RP) (n=6), radiation therapy (RT) (n=6), brachytherapy (n=2), RP+salvage prostate fossa RT (n=14), and RP+salvage prostate fossa/lymph node RT (n=6). Median PSA level before imaging was 2 ng/mL (range, 0.16 to 79). Labeled choline PET/CT showed prostate, prostate fossa, or pelvic lymph node increased uptake in 17 studies, remote metastatic disease in 9 studies, and failed to identify the cause for biochemical failure in 7 scans.PET/CT altered treatment approach in 18 of 33 (55%) patients (P=0.05). Sixteen of 27 patients (59%) treated previously with radiation were retreated with RT and delayed or eliminated androgen deprivation therapy: 1 received salvage brachytherapy, 10 received salvage pelvic lymph node or prostate fossa irradiation, 2 brachytherapy failures received salvage prostate and lymph nodes IMRT, and 3 with solitary bone metastasis were treated with radiosurgery. Eleven of 16 patients retreated responded to salvage therapy with a significant PSA response (<0.2 ng/mL), 2 patients had partial biochemical responses, and 3 patients failed. The median duration of response was 500+/-447 days. Two of 6 patients with no prior RT were referred for salvage prostatic fossa RT: 1 received dose escalation for disease identified in the prostate fossa and another had inclusion of "hot" pelvic lymph nodes in the treatment volume. CONCLUSIONS:: These early results suggest that labeled choline PET/CT imaging performed according to current NCCN guidelines may change management and improve care in prostate cancer patients with biochemical failure by identifying patients for referral for salvage radiation therapy, improving radiation planning, and delaying or avoiding use of androgen deprivation therapy.

BACKGROUND: Spine surgery has been transformed significantly by the growth of minimally invasive surgery (MIS) procedures. Easily marketable to patients as less invasive with smaller incisions, MIS is often perceived as superior to traditional open spine surgery. The highest quality evidence comparing MIS with open spine surgery was examined. METHODS: A systematic review of randomized controlled trials (RCTs) involving MIS versus open spine surgery was performed using the Entrez gateway of the PubMed database for articles published in English up to December 28, 2015. RCTs and systematic reviews of RCTs of MIS versus open spine surgery were evaluated for three particular entities: Cervical disc herniation, lumbar disc herniation, and posterior lumbar fusion. RESULTS: A total of 17 RCTs were identified, along with six systematic reviews. For cervical disc herniation, MIS provided no difference in overall function, arm pain relief, or long-term neck pain. In lumbar disc herniation, MIS was inferior in providing leg/low back pain relief, rehospitalization rates, quality of life improvement, and exposed the surgeon to >10 times more radiation in return for shorter hospital stay and less surgical site infection. In posterior lumbar fusion, MIS transforaminal lumbar interbody fusion (TLIF) had significantly reduced 2-year societal cost, fewer medical complications, reduced time to return to work, and improved short-term Oswestry Disability Index scores at the cost of higher revision rates, higher readmission rates, and more than twice the amount of intraoperative fluoroscopy. CONCLUSION: The highest levels of evidence do not support MIS over open surgery for cervical or lumbar disc herniation. However, MIS TLIF demonstrates advantages along with higher revision/readmission rates. Regardless of patient indication, MIS exposes the surgeon to significantly more radiation; it is unclear how this impacts patients. These results should optimize informed decision-making regarding MIS versus open spine surgery, particularly in the current advertising climate greatly favoring MIS.

BACKGROUND CONTEXT: Spine surgery has been transformed significantly over the past decade by the growth of minimally invasive surgery (MIS) procedures. Easily marketable to patients as less invasive with smaller incisions, it can be easy to perceive MIS as superior to traditional open spine surgery. However, this perception has yet to be addressed via a systematic review of the highest quality of evidence comparing MIS with open spine surgery. PURPOSE: To review the highest quality of evidence comparing MIS with open spine surgery. STUDY DESIGN/SETTING: Evaluation of MIS vs. open spine surgery for cervical disc herniation, lumbar disc herniation, and posterior lumbar fusion using Class I and Class II evidence. PATIENT SAMPLE: Patients included in published Class I and Class II evidence comparing MIS with open spine surgery. OUTCOME MEASURES: Quality of life, axial pain relief, extremity pain relief, hospital stay duration, infection, nerve root injury, durotomy, readmission rate, reoperation rate, blood loss, medical complications, societal cost, time to return to work, fusion rate, clinical outcome, radiographic outcome and radiation exposure. METHODS: A comprehensive search for randomized controlled trials involving MIS vs. open spine surgery was made using the Entrez gateway of the Pubmed database for articles published in English up to 12/28/15. Randomized controlled trials (RCTs) and systematic reviews of RCTs of MIS vs. open spine surgery were evaluated for three particular entities: cervical disc herniation, lumbar disc herniation, and posterior lumbar fusion. Additional Class II studies were included for clinical aspects not addressed in the RCTs. RESULTS: A total of 17 RCTs were identified, along with six systematic reviews. For cervical disc herniation, MIS was no different with regard to overall function, arm pain relief, or long-term neck pain. In lumbar disc herniation, MIS was inferior in providing leg or low back pain relief, more likely to require rehospitalization, inferior in improving quality-of-life, and exposed the surgeon to at least 10 times more radiation in return for shorter hospital stay and lower risk of surgical site infection. In disc herniation of either the cervical or lumbar spine, MIS trended towards higher rates of nerve root injury, durotomy, and reoperation, but none were statistically significant. In posterior lumbar fusion, MIS transforaminal lumbar interbody fusion (TLIF) had significantly reduced 2-year societal cost, fewer medical complications, reduced time to return to work, and improved short-term Oswestry Disability Index scores at the cost of higher revision rates, higher readmission rates, and more than twice the amount of intraoperative fluoroscopy; there was no difference in fusion rate, clinical outcome or radiographic outcome. CONCLUSIONS: The highest levels of evidence do not support MIS over open surgery for either cervical or lumbar disc herniation. However, for fusion cases, MIS TLIF demonstrates advantages, most prominently in reduced hospitalization, societal cost, and time to return to work at the cost of higher revision and readmission rates. Regardless of patient indication, MIS results in significantly more radiation exposure to the surgeon; it is unclear whether this exposure impacts patients as well. These results should be made clear to patients in order to give them the best chance to make an informed decision when choosing MIS vs. open spine surgery, particularly given the current medical advertising climate which greatly favors the choice of MIS